Role of Complement Regulatory Proteins in the Survival of Murine Allo-transplanted Sertoli Cells.
10.3346/jkms.2007.22.2.277
- Author:
Hak Mo LEE
1
;
Byoung Chol OH
;
Dong Pyo LIM
;
Dong Sup LEE
;
Jaejin CHO
;
Gene LEE
;
Jeong Ryul LEE
Author Information
1. Department of Thoracic and Cardiovascular Surgery, College of Medicine, Seoul National University, Seoul, Korea. jrl@plaza.snu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Sertoli Cells;
Fas Ligand;
Transfroming Growth Factor Beta1;
Clusterin;
Complement Regulatory Protein;
CD59
- MeSH:
Transplantation, Homologous/immunology;
Transforming Growth Factor beta1/*immunology;
Sertoli Cells/*immunology/*transplantation;
Mice, Inbred C57BL;
Mice;
Male;
Graft Survival/*immunology;
Female;
Fas Ligand Protein/*immunology;
Complement System Proteins/*immunology;
Clusterin/*immunology;
Cells, Cultured;
Cell Survival;
Animals
- From:Journal of Korean Medical Science
2007;22(2):277-282
- CountryRepublic of Korea
- Language:English
-
Abstract:
Sertoli cells (SC) are known to contain immunoprotective properties, which allow them to survive as allografts without the use of immunosuppressive drugs. Experiments were designed to determine which factors are related to prolonged survival of allogeneic SC. Balb/c derived Sertoli (TM4) and colon cancer (CT-26) cell lines were implanted beneath the kidney capsule of non-immunosuppressed C57BL/6 mice and compared their survival as allografts. Compared to TM4 graft, which survived more than 7 days after transplantation, CT-26 showed massive infiltration of polymorphonuclear cells, necrosis and enlargement of draining lymph nodes. Cultured cell lines showed no differences in their expression patterns of FasL, TGF beta1, clusterin and two complement regulatory proteins (CRP, i.e., membrane cofactor protein, MCP; decay accelerating factor, DAF), but protectin (CD59), another member of CRP was expressed only on TM4. These results suggest that CD59 and unknown factors may contribute to the prolonged survival of SC in non-immunoprivileged sites.
